ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

7/31/24 5:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALXO alert in real time by email

Conference Call and Webcast Today at 4:30 PM EDT

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.

To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 9637001. To access the live and archived webcast of the conference call, please visit the News & Events section (see "Events") of the Company's website at www.alxoncology.com, where a slide presentation will be referenced during the event.

Company Contact: Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology, [email protected], (650) 466-7125

Investor Contact: Malini Chatterjee, Ph.D, Blueprint Life Science Group, (917) 330-4269

Media Contact: Audra Friis, Sam Brown, Inc., [email protected], (917) 519-9577

Get the next $ALXO alert in real time by email

Date	Price Target	Rating	Analyst
3/8/2024	$10.00 → $14.00	Buy → Hold	Stifel
12/8/2023	$8.00 → $18.00	Hold → Buy	Jefferies
3/1/2022	$60.00 → $36.00	Buy	Stifel
12/22/2021	$65.00 → $25.00	Buy → Hold	Jefferies
9/30/2021	$106.00	Buy	Stifel

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Chat with this insight

Recent Analyst Ratings for $ALXO

$ALXO SEC Filings

ALX Oncology Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

$ALXO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ALXO Market Insights

Live Market Insights

$ALXO Press Releases

Fastest customizable press release news feed in the world

$ALXO Leadership Updates

Live Leadership Updates

$ALXO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ALXO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$ALXO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

SVP, FINANCE AND CAO Pinto Shelly sold $1,455 worth of shares (564 units at $2.58), decreasing direct ownership by 0.61% to 91,549 units (SEC Form 4)

CHIEF MEDICAL OFFICER Randolph Sophia sold $3,522 worth of shares (1,365 units at $2.58), decreasing direct ownership by 0.42% to 325,711 units (SEC Form 4)

HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $25 Price Target

ALX Oncology Reported Phase 1 ASPEN-07 Data In in Patients with Advanced Bladder Cancer AT ASCO 2024; Initial Activity Showed Tumor Reduction In The Majority Of Evaluable Patients

Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdings

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Announces November Investor Conference Participation

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology downgraded by Stifel with a new price target

ALX Oncology upgraded by Jefferies with a new price target

Stifel reiterated coverage on ALX Oncology Holdings with a new price target

Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

Lettmann Jason bought $49,771 worth of shares (4,400 units at $11.31), increasing direct ownership by 3% to 171,620 units (SEC Form 4)

Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

$ALXO Financials

Live finance-specific insights

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

Recent Analyst Ratings for
$ALXO

$ALXO
SEC Filings

$ALXO
Insider Trading

$ALXO
Market Insights

$ALXO
Press Releases

$ALXO
Leadership Updates

$ALXO
Analyst Ratings

$ALXO
Insider Purchases

$ALXO
Large Ownership Changes

$ALXO
Financials